Innate Pharma (IPHA) Assets Average (2018 - 2025)

Innate Pharma (IPHA) has reported Assets Average for 7 consecutive years, with $88.6 million the latest figure, recorded in Q4 2025.

• Quarterly Assets Average fell 40.72% year-over-year to $88.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $88.6 million (down 40.72% YoY) and the FY2025 annual result came in at $98.9 million, down 39.29% from the prior year.
• Assets Average fell to $88.6 million in Q4 2025 per IPHA's latest filing, from $116.1 million in the prior quarter.
• Over the last five years, Assets Average for IPHA reached as high as $326.4 million in Q2 2021 and fell as low as $88.6 million in Q4 2025.
• A 5-year average of $219.4 million and a median of $219.8 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2021 — Assets Average tumbled 99.82% — and 2022, when it slipped 4.48%.
• Year by year, Assets Average stood at $303.7 million in 2021, then decreased by 10.12% to $273.0 million in 2022, then retreated by 21.99% to $212.9 million in 2023, then declined by 29.84% to $149.4 million in 2024, then plunged by 40.72% to $88.6 million in 2025.
• According to Business Quant data, Assets Average over the past three periods registered $88.6 million, $116.1 million, and $149.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.